Physician profile
Brian Jaffe
NPI 1346401023
$4,006.48
in general payments reported to CMS, 2019-2025
31 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what 84% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $53.29 · 2021: $47.00 · 2022: $257 · 2023: $734 · 2024: $1,165 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,489 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,488.50 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,190.05 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,119.04 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $288.36 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $173.10 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.55 | 2022-2025 | Ofev |
| Philips North America LLC | $111.63 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Verona Pharma, INC. | $83.39 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $81.75 | 2024-2025 | Aralast |
| United Therapeutics Corporation | $74.63 | 2023-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $64.87 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Avadel Cns Pharmaceuticals, LLC | $64.25 | 2024-2025 | Lumryz |
| Amgen INC. | $59.37 | 2023-2025 | Tezspire |
| Genentech USA, INC. | $52.24 | 2024-2025 | Xolair |
| Jazz Pharmaceuticals INC. | $49.62 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $49.10 | 2025 | Purified Cortrophin Gel |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $46.92 | 2023 | Hillrom - Life 2000 Ventilation System |
| Harmony Biosciences LLC | $45.14 | 2023 | Wakix |
| Grifols USA, LLC | $44.50 | 2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $35.21 | 2025 | Zepbound |
| Insmed, INC. | $32.93 | 2023-2025 | Brinsupri, Arikayce |
| Mylan Specialty L.P. | $30.57 | 2023-2024 | Yupelri |
| Vapotherm INC | $29.19 | 2022 | |
| Sunovion Pharmaceuticals INC. | $27.99 | 2019 | |
| Soleno Therapeutics, INC. | $21.93 | 2025 | Vykat Xr |
| Novartis Pharmaceuticals Corporation | $20.20 | 2025 | |
| Axsome Therapeutics, INC. | $18.96 | 2025 | Sunosi |
| Covis Pharma Gmbh | $18.51 | 2022 | |
| Abbvie INC. | $18.39 | 2021 | |
| Resmed Corp | $17.34 | 2020 | |
| Merck Sharp & Dohme LLC | $13.54 | 2023 | Belsomra |
| Circassia INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.